A New Royalty Stream For PDL Bio (PDLI)
PDL BioPharma, Inc. (NASDAQ: PDLI) appears to have a new royalty stream coming its way. The company announced this morning that it is now set to start receiving royalty payments from Roche's Genentech unit on sales of Pertuzumab.
Genentech has now notified PDL that Pertuzumab, which will be marketed under the brand name Perjeta, is a royalty license product.
Posted on July 4, 2012, in Uncategorized. Bookmark the permalink. Leave a Comment.


Leave a Comment
Comments (0)